In spite of a surge in happy stories about biotech companies able to attract powerful investors, not everyone is able to replenish their money pits. The young Aarhus-based biotech company Skau Vaccines, chaired by biotech heavyweight Peter Wulff, is one of the companies that have walked away from investor meetings empty handed .
“It has been very difficult for Skau to attract capital following the investment from Østjysk Innovation, and the company has been living off of funding from various projects. It looks like they will now get some money from a new EU program, so the company will soldier on. But it’s difficult to convince funds to invest in an early-stage project,” Peter Wulff tells Medwatch.